Squarepoint Ops LLC Purchases 23,312 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Squarepoint Ops LLC increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 27.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,563 shares of the company’s stock after purchasing an additional 23,312 shares during the quarter. Squarepoint Ops LLC owned approximately 0.18% of Kymera Therapeutics worth $3,241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its position in shares of Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after buying an additional 295 shares during the last quarter. Comerica Bank boosted its holdings in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares in the last quarter. Keudell Morrison Wealth Management boosted its holdings in Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after acquiring an additional 480 shares in the last quarter. Congress Asset Management Co. MA increased its position in Kymera Therapeutics by 1.2% during the 1st quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after purchasing an additional 533 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in Kymera Therapeutics by 4.7% in the 1st quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after purchasing an additional 547 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research report on Monday, August 26th. Oppenheimer increased their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. B. Riley increased their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. Finally, Wells Fargo & Company boosted their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $49.00.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the completion of the transaction, the insider now directly owns 95,470 shares in the company, valued at approximately $4,373,480.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bruce Booth sold 453,960 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 495,605 shares of company stock valued at $19,303,364. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $46.57 on Wednesday. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -18.55 and a beta of 2.22. The stock has a 50-day moving average of $45.95 and a 200 day moving average of $39.42. Kymera Therapeutics, Inc. has a one year low of $9.60 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $12.55 million. During the same period in the previous year, the company earned ($0.67) earnings per share. The firm’s quarterly revenue was up 55.2% on a year-over-year basis. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.